Plus Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Austin, texas, may 06, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that it has entered into a securities purchase agreement with new institutional investors and company insiders to raise up to approximately $18 million in gross proceeds, including initial upfront funding of approximately $6.5 million, and up to an additional approximately $11.5 million upon cash exercise of accompanying warrants at the election of the investors. the financing includes participation from aigh capital management llc with additional participation from new healthcare-focused institutional investors as well as certain company insiders.

Plus now has $23 million in active awards support for the company's targeted radiotherapeutic pipeline funding for pediatric brain cancer treatment is expected to begin in q3 2024,  pending contract finalization austin, texas, april 22, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced it has been selected for funding by the department of defense (dod) office of the congressionally directed medical research programs (cdmrp). the award is expected to commence in q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer.

The addition of both dr. brenner and dr. blouw substantially expands plus internal expertise in key areas dr. brenner will maintain his academic commitments but will greatly contribute to plus' scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (cns) cancers dr. blouw is an expert in cns tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid austin, texas, april 09, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that andrew brenner, m...

Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the respect-lm phase 1 dose escalation trial with rhenium ( 186 re) obisbemeda for leptomeningeal metastases (lm)

Plus receives $3.3m in grant revenue in q4 2023 forecasts additional $6.9m of grant revenue for 2024 enters into debt restructuring deal with pershing capital to reduce 2024 cash burn by $3.7m austin, texas, dec. 18, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced financial updates and guidance for 2024. plus is currently in the second year of a cancer prevention and research institute of texas (cprit) award totaling $17.8 million.

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.

Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth and upside.

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.

Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting

AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM) .

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 3:00 p.m. ET at the Lotte New York Palace in New York, NY.

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capita Operator Good afternoon, ladies and gentlemen.

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.